Cover Image

全球C型肝炎病毒 (HCV) 市場

Global Hepatitis C Virus (HCV) Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 354601
出版日期 內容資訊 英文 60 Pages
Back to Top
全球C型肝炎病毒 (HCV) 市場 Global Hepatitis C Virus (HCV) Market Report: 2016 Edition
出版日期: 2016年03月16日 內容資訊: 英文 60 Pages

本報告提供全球C型肝炎病毒 (HCV) 市場相關調查分析,市場概要,市場動態,競爭情形,主要企業簡介等系統性資訊。

第1章 HCV市場

  • 簡介
  • 種類
  • 感染的擴大
  • 重感染
  • 感染的迴避

第2章 全球HCV市場

  • 全球HCV銷售額:各金額
  • 全球HCV盛行率:各地區

第3章 全球HCV市場:各地區

  • 美國市場
  • EU的HCV銷售額:各金額
  • 日本的HCV銷售額:各金額
  • 其他地區的HCV銷售額:各金額

第4章 市場動態

  • 成長推動因素
  • 趨勢與發展
  • 課題

第5章 競爭情形

  • 全球市場
  • 全球產品銷售額
  • Viekira vs. Harvoni:目前美國市場方案
  • Viekira vs. Harvoni:未來的美國市場方案

第6章 企業簡介

  • 產業概要、財務概要、產業策略

第7章 市場預測

  • 市場預測
  • 預測手法



Hepatitis C Virus (HCV) is an infection which affects the liver which may lead to serious consequences if not taken care of. It spreads through infected blood transfusions and poorly sterilized medical equipments. The number of patients has increased significantly because its symptoms take time to be recognized before the patient progresses towards a clinically visible liver damage which worsens the situation since it may lead to liver damage or even failure. There was no proper therapy for HCV before 2010 but the coming of therapies like Sovaldi and Harvoni by Gilead and Viekira Pak by AbbVie has improved the scenario. Also the steps taken like proper blood screening is also helping in identifying the patients.

The key factors which are anticipated to drive HCV market include medical reimbursement because of the therapy being very costly, growth in the number of patients, relatively smaller period of drug treatment from before, treatment of the warehoused patients who were waiting for a better therapy and pricing discounts and better regimens because of the increased competition. Some of the significant developments of this industry include launch of the interferon free regimen and development of products like Sovaldi, Harvoni and Viekira Pak and the newly identified and diagnosed patients. However, the challenges to be faced ahead is more number of patients asking for reimbursement, increasing competition leading to price cutting, risk associated with drug development and regulatory risk.

This report offers a comprehensive analysis of the HCV market. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. On the contention front, the global HCV market is reined by few major players namely Gilead Sciences, AbbVie, Johnson & Johnson and Bristol-Myers Squibb. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

By combining SPSS Inc.'s data integration and analysis capabilities with our relevant findings, we have predicted the future growth of the market. We employed various significant variables that have an impact on this industry and created regression models with SPSS Base to determine the future direction of the industry. Before deploying the regression model, the relationship between several independent or predictor variables and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.

Table of Contents

1. HCV Market

  • 1.1. An Introduction
  • 1.2. Types of Hepatitis C Virus
  • 1.3. Ways of Spreading of HCV Infection
  • 1.4. HCV Co Infections
  • 1.5. Avoidance of HCV Infection

2. Global HCV Market

  • 2.1. Global HCV Sales by Value
  • 2.2. Global HCV Prevalence by Region

3. Global HCV Market by Region

  • 3.1. The US Market
    • 3.1.1. The US HCV Sales by Value
    • 3.1.2. The US HCV Market Dynamics
    • 3.1.3. HCV Patients Initiated Treatment with Sofosbuvir
  • 3.2. European Union HCV Sales by Value
  • 3.3. Japan HCV Sales by Value
  • 3.4. ROW HCV Sales by Value

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Impact of Reimbursement
    • 4.1.2. Growth in Number of Patients
    • 4.1.3. Smaller Period of Drug Treatment
    • 4.1.4. Improved Economic Growth
    • 4.1.5. Increasing Healthcare Expenditure
    • 4.1.6. Treatment of Warehoused Patients
    • 4.1.7. Global Ageing Population
    • 4.1.8. Pricing Discounts and Better Regimen
  • 4.2. Trends and Development
    • 4.2.1. Launch of Interferon Free Regimen and Development of New Products
    • 4.2.1. Newly Identified and Diagnosed Patients
  • 4.3. Challenges
    • 4.3.1. Increase in Number of Patients for Reimbursement
    • 4.3.2. Increased Competition leading to Price Cut
    • 4.3.3. Risk Associated with Drug Development and Patent
    • 4.3.4. Regulatory Risk

5. Competitive Landscape

  • 5.1. Global Market
  • 5.2. Global Product Sales
  • 5.3. Viekira Vs. Harvoni - Current US Market Scenario
  • 5.4. Viekira Vs. Harvoni - Future US Market Scenario

6. Company Profiles

  • 6.1. Gilead Sciences
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. AbbVie
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Johnson & Johnson
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. Bristol-Myers Squibb
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

7. Market Outlook

  • 7.1. Market Forecast
  • 7.2. Forecast Methodology
    • 7.2.1. Dependent and Independent Variables
    • 7.2.2. Correlation Analysis
    • 7.2.3. Regression Analysis

List of Charts

  • Types of Hepatitis C Virus (HCV)
  • Natural History of HCV Infection
  • Global HCV Market by Value (2011-2015)
  • HCV Genotype 1 Patients in Emerging Markets (2015)
  • Global Deaths Due to HCV (2010-2014)
  • The US HCV Market by Value (2011-2015)
  • The US HCV Market Dynamics (2014)
  • Total Estimated HCV Patients to be treated in US (2015)
  • Total Estimated Genotype1 Patients to be treated in the US (2015)
  • Estimated HCV Patients to be treated in the US (2016E-2029E)
  • Patients Initiating Treated with Sofosbuvir Based Regimen (2015)
  • HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Genotype (2015)
  • HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Fibrosis Score (2015)
  • HCV Patients Initiated Treatment with Sofosbuvir based Regimen by Patient Type (2015)
  • EU HCV Market by Value (2011-2015)
  • Estimated Number of Patients to be treated in EU (2016E - 2029E)
  • Japanese HCV Market by Value (2011-2015)
  • Estimated Number of Patients to be treated in Japan (2016E-2029E)
  • Rest of World HCV Market by Value (2011-2015)
  • Reimbursement Situation (2015)
  • Global GDP Growth (2006-2014)
  • Global Healthcare Expenditure (2007-2014)
  • Frequency of Patients Warehoused Currently by Doctors (2014)
  • Warehoused Patients Expected to be treated in 2015
  • Warehoused Patients Expected to be treated in 2016
  • Global Ageing Population (2006-2014)
  • Mix of Doctors in Survey (2014)
  • Frequency of New Patients Treated per Month (2014)
  • Newly Identified Patients per Year (2015E-2029E)
  • Percentage of New Diagnosed Patients (2015E - 2029E)
  • Global Market Share of HCV and HBV (2014)
  • Global Market Share of HCV and HBV (2020E)
  • Global Sales of Sovaldi, Harvoni and Viekira Pak (2015)
  • The US Market Share of Viekira and Harvoni (2014)
  • Factors Affecting the Growth of Viekira (2014)
  • Factors affecting while Prescription of Harvoni and Viekira (2014)
  • The US Market Share by Company (2016E)
  • Gilead Revenue and Net Income (2010-2014)
  • AbbVie Revenue and Net Income (2010-2014)
  • J&J's Consumer Sales by Segment (2014)
  • J&J's Pharmaceutical Sales by Segment (2014)
  • Global Medical Devices Sales by Segment (2014)
  • Johnson & Johnson Revenue and Net Income (2010-2014)
  • J&J's Research & Development Expenses by Segment (2013-2014)
  • Bristol Myers Squibb Revenue and Net Income (2010-2014)
  • Bristol-Myers Revenue by Region (2014)
  • Global HCV Market Forecast (2014-2019E)

List of Tables

  • Different Ways of Transmission of HCV
  • Global HCV Prevalence by Region (2014)
  • Summary of Survey Population
  • Market Share Based on Contracted Lives
  • Clinical Factors Affecting Market Share of AbbVie Vs. Gilead (2014)
  • Cure Rates with New Direct Acting anti-Viral - DAA (2014)
  • Viekira Pak Pill Order
  • Future Regimens of Gilead, AbbVie and Merck
  • Dependent & Independent Variables (2011-2015)
  • Correlation Matrix
  • Model Summary - Coefficient of Determination
  • Regression Coefficients Output
Back to Top